New research finds chronic pain is five times more common in patients with Parkinson’s disease compared to age-matched ...

Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced ...

If you’ve been wanting to add a retinol into your skin care routine but don’t know where to start, we tapped a few experts ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

Ensho Therapeutics has presented additional data supporting NSHO-101, also referred to as EA1080, as an oral one-time-a-day ...

Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its ...

After receiving the Day 74 letter, which outlines the FDA’s initial assessment of the application, the agency accepted Epioxa ...

Microbiota transplantation is safe and effective for treating clostridioides difficile infections, according to a clinical ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

The following is a summary of “Spaced Transcranial Direct Current Stimulation for Major Depression,” published in the January ...